ImmunityBio Inc. (NASDAQ: IBRX) announced survey data from UK adults with non-muscle-invasive bladder cancer showing varied treatment preferences following BCG therapy failure. The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research conference in Philadelphia.

The study, conducted with Fight Bladder Cancer, surveyed 86 UK adults currently receiving or previously treated with Bacillus Calmette-Guérin therapy for high-risk non-muscle-invasive bladder cancer. Researchers used online questionnaires, interviews and focus groups to examine patient preferences between radical cystectomy and bladder-sparing treatments.

Results showed patients actively receiving BCG were more likely to favor bladder preservation strategies, while those who previously underwent radical cystectomy were more likely to support repeating that procedure. Older participants demonstrated lower preference for radical cystectomy.

The survey identified clinical effectiveness as the most important factor influencing treatment decisions, including impact on cancer recurrence, progression and life expectancy. Quality-of-life considerations varied among patients, with male participants expressing greater concern about daily-life disruption from radical cystectomy.

"Treatment decisions for patients with BCG-unresponsive NMIBC are deeply personal and often complex," said Patrick Soon-Shiong, founder and executive chairman of ImmunityBio.

The researchers concluded that treatment priorities varied widely among participants, with some prioritizing cancer control while others emphasized quality of life and bladder preservation. Many patients indicated willingness to accept trade-offs such as more frequent hospital visits to avoid radical cystectomy.

Fight Bladder Cancer is a UK patient advocacy organization focused on supporting people affected by bladder cancer and funding research to improve diagnosis and treatment.